Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first ...
Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...
LONDON--(BUSINESS WIRE)--Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ ...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio’s (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene ...
Single-use systems streamline CGT manufacturing by reducing cleaning validation and enabling quick changeovers, essential for ...
CAMBRIDGE, England & BAD HOMBURG, Germany--(BUSINESS WIRE)--Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that ...
Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after ...
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...
Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indicationsSOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE ...
SOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback